The Medical Freedom Channel

“GlaxoSmithKline Plc’s experimental vaccine Cervarix has proved more than 90 percent effective in preventing precancerous lesions due to two types of a virus responsible for most cases of cervical cancer. Interim results from the biggest cervical cancer vaccine trial to date, published on Thursday in the Lancet medical journal, confirm previous promising data. Cervarix is a rival to Merck & Co. Inc.’s similar product Gardasil. Analysts expect both vaccines will be multibillion-dollar sellers. Gardasil, however, may have the edge, since it is already established in international markets. So far, the only major market where Cervarix has a green light is Australia. Glaxo expects to launch it in Europe in the second half of this year but in the United States — the world’s top market — it will not go on sale before 2008.” (06/28/07)